SHORT syndrome features short stature and insulin resistance consistent with impaired ligand-induced p110α action, a phenotype distinct from the enhanced insulin sensitivity produced by genetic ablation of one or more Pik3r1 products in mice (Chen et al., 2004; Fruman et al., 2000; Mauvais-Jarvis et al., 2002). Here, INS is linked to SHORT syndrome.